News and Announcements
Imugene Receives Acceptance for Leading Clinical Drug
- Published February 27, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company has been developing a leading clinical drug called HER-Vaxx for treatment of gastric cancer patients.
KEY TAKEAWAYS:
- Today the company received a Notice of Acceptance form the Australian Patent Office for Patent Application.
Gastric or stomach cancer is the second most common cause of cancer-related death in the world and the fourth most commonly diagnosed cancer. Aa recently published in the journal BMC Cancer, and announced February 13, 2017, the enhanced formulation of HER-Vaxx incorporates an existing, clinically and commercially validates vaccine carrier protein.
“The strengthening of our patent portfolio is an important milestone and underpins our commercialisation strategy,” said Ms. Leslie Chong, Chief Executive Officer of Imugene.
Also adding “This new patent protects HER-Vaxx until 2036 which is significantly longer than the vast majority of completing clinical stage products and technologies. The additional patent life adds an additional six years to the time HER-Vaxx could remain generating peak sales, adding to the total amount of potential sales achievable by HER-Vaxx and hence significantly increasing the value of HER-Vaxx.”
To read the full ASX Announcement, please click here.
Company Updates
Everything is now competing for the same dollar
Key takeaways As recently as 2022, Germany and Japan could borrow for 30 years at close to zero. That world is gone, and AI is now bidding for what is left. Over the past fortnight, I listened to founders, operators and allocators describe where their industries are heading. They covered four very different frontiers. Each […]
Australia has not held 90 days of fuel since 2012. The fix may start at a sewage plant.
A decommissioned council treatment site in Bundaberg is being built into a $188.9 million biorefinery. Its managing director is candid that the largest revenue line is not yet contracted. Australia has not met its international 90-day fuel reserve obligation since 2012. Around 90 per cent of the country’s liquid fuel is imported. Andy Whitmore, Managing […]
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
Backed By Leading Investment Groups and Family Offices
